BioMarin Pharmaceutical (BMRN) said Tuesday that it has completed its all-cash acquisition of Inozyme Pharma (INZY) for $270 million, or $4 per share.

The company said the move strengthens its enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy in development for ENPP1 Deficiency-a rare genetic disease that affects blood vessels, soft tissues, and bones.

The company said Inozyme shares have now been delisted from the Nasdaq Global Select Market.